Lei Yan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lei Yan has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chen Xue
Department of Radiology The Affiliated Brain Hospital of Nanjing Medical University Nanjing China
1 shared publication - Chenxi Pan
Department of Neurology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication Dengke Jia
College of Medical Science China Three Gorges University Yichang China
1 shared publicationFangqi Xia
College of Medical Science China Three Gorges University Yichang China
1 shared publicationGuangfu Xu
College of Medical Science China Three Gorges University Yichang China
1 shared publication- Hao Zhou
Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China
1 shared publication
Latest Publications
- Open Access
- 7 August 2023
- Published by Elsevier in Neurobiology of Disease
- Vol. 185, 106254
Unraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease
- 7 August 2023
- Published by Elsevier in Neurobiology of Disease
- Vol. 185, 106254
Open AccessUnraveling neurotransmitter changes in de novo GBA-related and idiopathic Parkinson's disease
- RetractedOpen Access
- 17 August 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (18) , 8863-8876
Astragaloside IV ameliorates fat metabolism in the liver of ageing mice through targeting mitochondrial activity
Astragaloside IV (AST) is a major bioactive compound of Radix Astragali with medical and health benefits. Previous studies have found that AST can reduce the body weights of high‐fat diet fed mice. However, the effect of AST on fat metabolism of ageing mice is unclear. In this study, naturally ageing mice were administered intragastrically with AST at 30 mg/kg/day (ageing + AST‐L group) and 90 mg/kg/day (ageing + AST‐H group) for 16–20 months. Adult (4 months old) and ageing mice were given 1% sodium carboxyl methylcellulose as vehicle. Energy metabolism‐related biological parameters of living mice were examined. Moreover, mRNA and protein levels of key enzymes/proteins involved in triglyceride (TG) lipolysis, fatty acid β‐oxidation (FAO), ketone body (KB) production and mitochondrial respiratory chain were also examined after sacrifice. Results demonstrated that treatment with AST significantly reduced body weight, white fat and liver/body weight ratio of ageing mice, significantly reduced serum/hepatic TG levels, respiratory quotient, promoted fatty acid mobilization in white adipose tissue, mitochondrial FAO and KB production and mitochondrial biosynthesis/functions in the liver of ageing mice. AST also up‐regulated the expression of phosphorylated AMP‐activated protein kinase, acetyl‐CoA carboxylase, acetyl‐coenzyme A synthetase, carnitine palmitoyltransferase 1a/1b, enoyl coenzyme A hydratase‐short chain, acyl‐CoA dehydrogenase medium chain and mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA synthase‐2 involved in fat metabolism. These results indicated that mitochondrial activity could be the target of AST to treat abnormal fat metabolism during ageing.
- 17 August 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (18) , 8863-8876
RetractedOpen AccessAstragaloside IV ameliorates fat metabolism in the liver of ageing mice through targeting mitochondrial activity
Astragaloside IV (AST) is a major bioactive compound of Radix Astragali with medical and health benefits. Previous studies have found that AST can reduce the body weights of high‐fat diet fed mice. However, the effect of AST on fat metabolism of ageing mice is unclear. In this study, naturally ageing mice were administered intragastrically with AST at 30 mg/kg/day (ageing + AST‐L group) and 90 mg/kg/day (ageing + AST‐H group) for 16–20 months. Adult (4 months old) and ageing mice were given 1% sodium carboxyl methylcellulose as vehicle. Energy metabolism‐related biological parameters of living mice were examined. Moreover, mRNA and protein levels of key enzymes/proteins involved in triglyceride (TG) lipolysis, fatty acid β‐oxidation (FAO), ketone body (KB) production and mitochondrial respiratory chain were also examined after sacrifice. Results demonstrated that treatment with AST significantly reduced body weight, white fat and liver/body weight ratio of ageing mice, significantly reduced serum/hepatic TG levels, respiratory quotient, promoted fatty acid mobilization in white adipose tissue, mitochondrial FAO and KB production and mitochondrial biosynthesis/functions in the liver of ageing mice. AST also up‐regulated the expression of phosphorylated AMP‐activated protein kinase, acetyl‐CoA carboxylase, acetyl‐coenzyme A synthetase, carnitine palmitoyltransferase 1a/1b, enoyl coenzyme A hydratase‐short chain, acyl‐CoA dehydrogenase medium chain and mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA synthase‐2 involved in fat metabolism. These results indicated that mitochondrial activity could be the target of AST to treat abnormal fat metabolism during ageing.